Delayed Hematologic Toxicities Following Axicabtagene Ciloleucel and Tisagenlecleucel CAR-T Cell Therapy: A Retrospective Analysis of Lymphocytopenia, Neutropenia, and Thrombocytopenia
Asian journal of Current Research in Clinical Cancer · 2024
DOI: 10.51847/13fiaq9er0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian journal of Current Research in Clinical Cancer, 2024. Verfasst von Carina Bona und 1 weiteren Autor:innen. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
This study provides a 2024 update on survival outcomes and the frequency of hematologic complications, specifically lymphocytopenia, neutropenia, and thrombocytopenia, in patients treated with axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) CAR-T cell therapies. The study examined 56 patients diagnosed with diffuse large B-cell lymphoma who underwent CAR-T cell therapy from 2019 to March 2024. Among them, 34 patients received axi-cel (group A), and 22 patients were treated with
Zitieren
APA
Bona, C., & Lozano, R. (2024). Delayed Hematologic Toxicities Following Axicabtagene Ciloleucel and Tisagenlecleucel CAR-T Cell Therapy: A Retrospective Analysis of Lymphocytopenia, Neutropenia, and Thrombocytopenia. Asian journal of Current Research in Clinical Cancer. https://doi.org/10.51847/13fiaq9er0
Vancouver
Bona C, Lozano R. Delayed Hematologic Toxicities Following Axicabtagene Ciloleucel and Tisagenlecleucel CAR-T Cell Therapy: A Retrospective Analysis of Lymphocytopenia, Neutropenia, and Thrombocytopenia. Asian journal of Current Research in Clinical Cancer. 2024. doi:10.51847/13fiaq9er0
BibTeX
@article{Bona2024,
author = {Bona, Carina and Lozano, Roberto},
title = {Delayed Hematologic Toxicities Following Axicabtagene Ciloleucel and Tisagenlecleucel CAR-T Cell Therapy: A Retrospective Analysis of Lymphocytopenia, Neutropenia, and Thrombocytopenia},
journal = {Asian journal of Current Research in Clinical Cancer},
year = {2024},
doi = {10.51847/13fiaq9er0}
}
EUVIMED